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Epidemiology of Vasomotor Rhinitis
Russell A. Settipane, MD
Abstract: Vasomotor rhinitis is the most common form of nonal-
lergic rhinitis, comprising approximately 71% of all nonallergic
rhinitis conditions. Although the epidemiology of this subtype of
nonallergic rhinitis has not been definitively studied, it is estimated
that 14 million Americans suffer from vasomotor rhinitis, with a
worldwide prevalence approaching 320 million.
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INTRODUCTION
Vasomotor rhinitis (VMR) is a subtype of nonallergicrhinitis (NAR) that is unrelated to allergy, infection,
structural lesions, systemic disease, or drug abuse. Be-
cause it is, by definition, an idiopathic form of rhinitis, a
diagnosis can be made only when all other forms of rhinitis
have been excluded. Determination of the epidemiology of
VMR is confounded by numerous challenges as shown in
Table 1. The first challenge in determining the epidemiol-
ogy of VMR is gaining agreement on the definition of this
form of rhinopathy. As with other forms of NAR, VMR is
characterized by periodic or perennial symptoms of rhinitis
that are not due to IgE-dependent events. A number of
consensus statements have put forth definitions of VMR,
the most recent being the report of the 2008 AAAAI Joint
Task Force on Practice Parameters, The diagnosis and
management of rhinitis: an updated practice parameter,
which defines VMR (idiopathic rhinitis) as a “heteroge-
neous group of patients with chronic nasal symptoms that
are not immunologic or infectious in origin and are usually
not associated with nasal eosinophilia.”1 The clinical char-
acteristics of VMR are further elaborated in the article by
Bernstein3 in this issue.
Because VMR is a diagnosis that essentially requires
the exclusion of all other forms of rhinitis, an appropriately
performed epidemiological study would require protocol
incorporating a multitude of standardized tests to rule out
all other forms of rhinitis. Appropriate testing might in-
clude those tests listed in Table 2. The article by Benniger
et al,5 which will appear in the next issue of this journal,
describes the proposed inclusion and exclusion criteria for
research studies in nonallergic rhinopathy, including
VMR, as agreed upon by the participants of this roundtable
meeting (see “Consensus Review and Definition of Non-
allergic Rhinitis With a Focus on Vasomotor Rhinitis,
Proposed To Be Known Henceforth as Nonallergic Rhi-
nopathy: Part 1. Introduction” in this Review Series issue
for the listing of participants). To date, no prospective
epidemiologic studies have applied such a protocol to
evaluate a large population of rhinitis patients. Conse-
quently, current estimates regarding the prevalence of
VMR are fairly crude.
METHODS
A literature search was performed using the follow-
ing terms: vasomotor rhinitis, nonallergic rhinitis, idio-
pathic rhinitis, nonallergic noninfectious rhinitis, preva-
lence, and epidemiology. On the basis of this search and
pertinent review articles, the reported prevalence rates of
NAR and subtypes were compiled and the prevalence of
VMR was extrapolated.
RESULTS
Relative Prevalence Rates of Allergic Rhinitis
Versus Nonallergic Rhinitis
Although no studies specifically designed to examine
the epidemiology of NAR or VMR have been reported, 9
epidemiologic studies report data regarding the relative
prevalence of NAR in comparison to that of AR (Table
3).6–15 Seven of the 9 studies employed skin testing with
variable techniques (prick, intradermal, both, or undefined)
to distinguish nonallergic rhinitis from allergic rhinitis.
Studies that did not discount positive skin tests unsup-
ported by history (all except Mullarkey et al) or that
employed intradermal (or undefined) skin testing6–9 are
likely to have overestimated the prevalence of allergic
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rhinitis and underdiagnosed VMR4. Two of the studies
used either history alone or ICD9 (International Classifi-
cation of Diseases, Ninth Revision) data to diagnose VMR,
both of which are not well-established for diagnostic
purposes.12,14 Because none of the studies assessed for the
presence of local (nasal) IgE production, known as entopy,
VMR may have been overdiagnosed in some cases.2
Despite the fact that some of these studies were per-
formed in allergy outpatient settings, which would be antic-
ipated to skew the reported prevalence rates toward the
diagnosis of AR, the findings are fairly consistent and inde-
pendent of the setting performed. These 9 studies, when
added in total, are heavily influenced by the enormity of the
data from Schatz et al, but when analyzed independently of
the Schatz data, they reveal a relative prevalence rate of 76%
allergic and 24% nonallergic—closely approximating a 3:1
ratio.
Relative Prevalence Rates of NAR Subtypes
Three studies were identified that attempted to system-
atically subtype NAR by performing testing that included, at
a minimum, nasal examination, skin testing for sensitivity to
specific aeroallergens, total IgE, nasal cytology, and sinus
x-rays (Table 4).6,7,16 Each of these 3 studies has significant
limitations. Symptoms were poorly characterized, irritant
triggers were not captured, skin test techniques were variably
defined, sinus imaging was limited to sinus x-rays (known to
have limited value), and nasal examination data were not
presented. However, each of these studies did include exam-
ination of nasal cytology (albeit with variable methodologies)
in an attempt to screen out NARES or eosinophilic rhinosi-
nustits.
The data from these 3 studies, when combined, total
200 NAR subjects. VMR was identified as the most common
subtype, making up 71% of NAR diagnoses, with nonallergic
rhinitis with eosinophilia syndrome (NARES) making up the
majority of the remaining diagnoses (Table 5). The defini-
TABLE 1. Challenges in Determining the Prevalence of
Vasomotor Rhinitis
Agreement on VMR definition
Requirement to rule out all other forms of rhinitis
Requirement to rule out chronic rhinosinusitis
Skin testing or determination of serum-specific IgE is required
Local IgE production without systemic detection may be present (entopy)2
Sinus imaging is rarely assessed in large epidemiologic studies
Nasal cytology is rarely assessed in large epidemiologic studies
TABLE 2. Diagnostic Tests to Exclude Other Forms of
Rhinitis4
CT imaging of the paranasal sinuses
Assays for specific IgE sensitivity
(a) Skin testing
(b) Serum testing
(c) Local (nasal) testing (entopy)2
Nasal cytology
Intranasal allergen challenge
Ingestion challenge (gustatory rhinitis)
Thyroid function testing
TABLE 3. Relative Rhinitis Prevalence by Author: Allergic Versus Nonallergic
Author Year N AR% NAR% NAR Defined
Mullarkey et al6 1980 142 48 52 No history of allergen exacerbation. Negative skin tests or 2
PSTs unsupported by history and an IgE level 50 U/mL
Enberg7 1989 128 64 36 Negative SPTs and IDs to 36 allergens
Togias8 1990 362 83 17 Negative skin tests
Leynaert et al10 1999 1142 75 25 Negative SPTs to 9 allergens
Settipane et al9 2001 975 77* 23 Negative skin tests
Mercer et al12 2002 278 78 22 Negative SPTs to 20 allergens
Bachert et al13 2006 743 75 24 History only
Mølgaard et al14 2007 1186 77 23 Negative SPTs to 10 allergens
Schatz et al15 † 2008 47,894 71 29 ICD9 Classification
Total 52,850 71 29
*Including 34% mixed.
†Subtotal without Schatz et al: 76% AR; 24% NAR.
Abbreviations: SPT, skin prick test; ID, intradermal; PST, positive skin test; ICD9, International Classification of Diseases, Ninth Revision.
TABLE 4. Tests Used to Characterize Nonallergic Rhinitis
Test Mullarkey et al6 Enberg7 Settipane and Klein16
Nasal exam   
Skin test   
RAST   
Total IgE   (partial) 
CBC   
ESR   
TSH   
Cytology   
Sinus x-ray   (partial) 
Abbreviations: RAST, radioallergosorbent test; CBC, complete blood count; ESR,
erythrocyte sedimentation rate; TSH, thyroid stimulating hormone.
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tions of the NAR subtypes, VMR and NARES, used in each
of the 3 studies differed slightly. Sex and age demographic
data suggest a 2:1 female-to-male ratio and a higher mean age
(40 years old) for VMR subjects as compared with that of
allergic rhinitis subjects.
DISCUSSION
Estimated Prevalence of Nonallergic Rhinitis in
the United States and Worldwide
The data from rhinitis epidemiology studies suggest
that the ratio of AR prevalence (pure and mixed combined) to
that of pure NAR is 3:1. This ratio can be extrapolated to
determine a conservative estimate of the prevalence of NAR
in the United States based on established prevalence rates of
AR. If the assumption is made that 20% of the population
suffers from AR,17 then on the basis of current population
estimates for the United States of just more than 300 mil-
lion,18 the US prevalence of AR is 60 million people. Apply-
ing the 3:1 (AR/NAR) ratio, approximately 20 million Amer-
icans would be expected to suffer from NAR (or
approximately 7% of the total population). Given a current
world population of 6.75 billion,18 similar extrapolation sug-
gests that approximately 450 million people suffer from NAR
worldwide. It is not known whether VMR is equally preva-
lent throughout the world and whether local weather (humid-
ity), climate, air pollution, or genetic factors affect VMR
prevalence.
Estimated Prevalence of VMR in the United
States and Worldwide
The studies by Mullarkey,6 Enberg,7 and Settipane16
unanimously support VMR as the most common NAR
subtype, making up approximately 71% of NAR diag-
noses, with NARES making up the majority of the remain-
ing NAR conditions. Applying the 71% frequency of VMR
occurrence to the 20 million Americans who suffer from
NAR, it would be estimated that VMR affects 14 million
people in the United States. Applying the same frequency
to the 450 million worldwide population suffering from
NAR yields an estimate of a worldwide prevalence of
VMR of 320 million.
Further Characterization of VMR
VMR is often described as being characterized by
nonallergic symptom triggers, including weather (changes in
temperature or relative humidity), alcohol, tobacco smoke,
dusts, automotive emission fumes, nonspecific irritant stimuli
such as chlorine, and odors such as bleach, perfume, or
solvents.1 Unfortunately, no epidemiologic data exist to fur-
ther categorize VMR based on trigger type. Sex and age
demographic data specific to VMR is limited, but can be
extrapolated from NAR data, suggesting a female predomi-
nance and an older population for NAR than for AR.4–6,8,14
However, the trend toward female predominance remains
unproven; it is possible that a study selection bias may have
resulted if, as suspected, more females than males entered
studies because of an increased likelihood to seek rhinitis
care.
CONCLUSIONS
Data regarding the prevalence of rhinitis, regardless
of the type, are difficult to interpret. Contributing to this
challenge is the observation that most population surveys
have flawed designs.1 Because skin testing or determina-
tion of serum-specific IgE is infrequently assessed in large
epidemiologic studies, allergic causation is often not ac-
curately differentiated from nonallergic causation. How-
ever, on the basis of the data that has been reported, it is
clear that VMR is, by far, the most common subtype of
NAR with a significant burden of illness in the United
States and worldwide.
REFERENCES
1. Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, et
al.; Joint Task Force on Practice; American Academy of Allergy,
Asthma & Immunology; American College of Allergy, Asthma and
Immunology; Joint Council of Allergy, Asthma and Immunology. The
diagnosis and management of rhinitis: an updated practice parameter. J
Allergy Clin Immunol. 2008;122(2 Suppl):S1–S84.
2. Rondo´n C, Romero JJ, Lo´pez S, Antu´nez C, Martín-Casan˜ez E, et al.
Local IgE production and positive nasal provocation test in patients with
persistent nonallergic rhinitis. J Allergy Clin Immunol. 2007;119:899–
905.
3. Bernstein J. Characteristics of nonallergic vasomotor rhinitis. World
Allergy Org J [serial online]. 2009;2:102–105.
TABLE 5. Prevalence of VMR in a Nonallergic Rhinitis Population by Study
Investigator N (% Female) Mean Age (Population) Definition of VMR VMR % (n, VMR/n, NAR)
Mullarkey et al6 73 (sex not reported) 37.5 (VMR); 25.1 (AR) Nasal congestion and/or rhinorrhea persisting for 3
months, with no Hx of allergen exacerbation;
negative skin tests or 2 positive skin tests
unsupported by Hx; IgE 50 U/mL; 25%
eosinophils
71% (52/73)
Enberg 7 46 (74%) 40.5 (NAR) Nasal Sx persisting for 1 year with no cause





78 (58%) 42 (NAR) Nasal congestion/rhinorrhea persisting for 3
months; negative skin tests; normal IgE; 5%
eosinophils on nasal smear
61% (44/72)
Total 191 40.5 71% (136/191)
Abbreviations: Hx, history; Sx, symptom.
WAO Journal • June 2009 Epidemiology of Vasomotor Rhinitis
© 2009 World Allergy Organization 117
4. Bernstein IL, Li JT, Bernstein DI, Hamilton R, Spector SL, et al.;
American Academy of Allergy, Asthma and Immunology; American
College of Allergy, Asthma and Immunology. Allergy diagnostic test-
ing: an updated practice parameter. Ann Allergy Asthma Immunol.
2008;100(3 Suppl 3):S1–148.
5. Benninger M, Kaliner M, Farrar J. Proposed inclusion/exclusion criteria
for nonallergic rhinopathy. World Allergy Org J [serial online]. 2009;2:
in press.
6. Mullarkey MF, Hill JS, Webb DR. Allergic and nonallergic rhinitis: their
characterization with attention to the meaning of nasal eosinophilia. J
Allergy Clin Immunol. 1980;65:122–126.
7. Enberg RN. Perennial nonallergic rhinitis: a retrospective review. Ann
Allergy. 1989;63:513–516.
8. Togias A. Age relationships and clinical features of nonallergic rhinitis.
J Allergy Clin Immunol. 1990;85:182.
9. Settipane RA, Lieberman P. Update on non-allergic Rhinitis. Ann
Allergy Asthma Immunol. 2001;86:494–507.
10. Leynaert B, Bousquet J, Neukirch C, Liard R, Neukirch F. Perennial
rhinitis: an independent risk factor for asthma in nonatopic subjects.
Results from the European Community Respiratory Health Survey. J
Allergy Clin Immunol. 1999;104:301–304.
11. Settipane RA. Rhinitis: a dose of epidemiological reality. Allergy
Asthma Proc. 2003;24:147–154.
12. Mercer MJ, van der Linde GP, Joubert G. Rhinitis (allergic and
nonallergic) in an atopic pediatric referral population in the grass-
lands of inland South Africa. Ann Allergy Asthma Immunol. 2002;
89:503–512.
13. Bachert C, van Cauwenberge P, Olbrecht J, van Schoor J. Prevalence,
classification and perception of allergic and nonallergic rhinitis in
Belgium. Allergy. 2006;61:693–698.
14. Mølgaard E, Thomsen SF, Lund T, Pedersen L, Nolte H, Backer V.
Differences between allergic and nonallergic rhinitis in a large sample of
adolescents and adults. Allergy. 2007;62:1033–1037.
15. Schatz M, Zeiger RS, Chen W, Yang SJ, Corrao MA, Quinn VP. The
burden of rhinitis in a managed care organization. Ann Allergy Asthma
Immunol. 2008;101:240–247.
16. Settipane GA, Klein DE. Non allergic rhinitis: demography of eosino-
phils in nasal smear, blood total eosinophil counts and IgE levels. N Engl
Reg Allergy Proc. 1985;6:363–366.
17. Settipane RA, Charnock DR. Epidemiology of rhinitis: allergic and
nonallergic. Clin Allergy Immunol. 2007;19:23–34.
18. U.S. and World Population Clocks - POPClocks [database online].
Washington, DC: U.S. Census Bureau, Population Division; 2006.
Updated November 22, 2006. Available at: http://www.census.gov/
main/www/popclock.html. Accessed January 03, 2009.
Settipane WAO Journal • June 2009
© 2009 World Allergy Organization118
